Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT06731478
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
726 Enrollment(s)
250 Study location(s)
INTERVENTIONAL (PHASE3)
Gastric Cancer


Gastroesophageal Junction Cancer
RECRUITING
NCT03424005
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
1,132 Enrollment(s)
47 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Metastatic Breast Cancer
NOT_YET_RECRUITING
NCT07701941
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
220 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Hormone Receptor Positive


HER2-low or HER2-ultralow


Unresectable or Metastatic Breast Cancer
RECRUITING
NCT07195149
Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
1,703 Enrollment(s)
18 Study location(s)
INTERVENTIONAL (PHASE3)
Chronic Coronary Syndrome


Stable Coronary Artery Disease CAD
RECRUITING
NCT07137416
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
36 Enrollment(s)
2 Study location(s)
INTERVENTIONAL (PHASE1)
Anatomic Stage III Breast Cancer AJCC v8


Anatomic Stage IV Breast Cancer AJCC v8


Invasive Breast Carcinoma


Locally Advanced Breast Carcinoma


Metastatic Breast Carcinoma


Metastatic HER2-Low Breast Carcinoma


Metastatic HER2-Positive Breast Carcinoma


Metastatic Hormone Receptor-Positive Breast Carcinoma


Metastatic Malignant Solid Neoplasm


Metastatic Triple-Negative Breast Carcinoma


Unresectable Breast Carcinoma


Unresectable HER2-Low Breast Carcinoma


Unresectable HER2-Positive Breast Carcinoma


Unresectable Hormone Receptor-Positive Breast Carcinoma


Unresectable Malignant Solid Neoplasm


Unresectable Triple-Negative Breast Carcinoma
RECRUITING
NCT07069712
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
100 Enrollment(s)
70 Study location(s)
INTERVENTIONAL (PHASE2)
Gastroesophageal Adenocarcinoma
RECRUITING
NCT05573893
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
800 Enrollment(s)
108 Study location(s)
OBSERVATIONAL (None)
Breast Neoplasms


Breast Cancer


Neoplasm Metastasis
ACTIVE_NOT_RECRUITING
NCT05048797
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
454 Enrollment(s)
130 Study location(s)
INTERVENTIONAL (PHASE3)
Locally Advanced or Metastatic Non-Small Cell Lung Cancer